MR1-1

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMR1-1
Drug Alias NameMR1-1MR1-1KDELMR1-1(d sFv)-PE38KDEL
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSupratentorial NeoplasmsBrain Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDuke University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDuke UniversityNational Institute Of Neurological Disorders And StrokeTeva Pharmaceutical Industries Ltd
Active IndicationsN/A
Inactive IndicationsSupratentorial NeoplasmsBrain Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A